Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications (Scientific Reports (2017) 7 (1450) DOI: 10.1038/s41598-017-01590-x);Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Cohen, Isaac V ^a   Makunts, Tigran ^a   Atayee, Rabia ^a   Abagyan, Ruben ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; DICLOFENAC; KETAMINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT;

DATA MINING; DEPRESSION; DRUG REPOSITIONING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION RETRIEVAL; PAIN; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; DATA MINING; DEPRESSION; DICLOFENAC; DRUG REPOSITIONING; HUMANS; INFORMATION STORAGE AND RETRIEVAL; KETAMINE; MINOCYCLINE; PAIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85018346126     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-14992-8     Document Type: Erratum

References (18)

1. Murray, C. J. & Lopez, A. D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 274, 740-743, doi: 10.1126/science.274.5288.740 (1996).
2. Kessler, R. C. et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105, doi: 10.1001/jama.289.23.3095 (2003).
3. Bromet, E. et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9, 90, doi: 10.1186/1741-7015-9-90 (2011).
4. Andrade, L. et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 12, 3-21, doi: 10.1002/(ISSN)1557-0657 (2003).
5. Sansone, R. A. & Sansone, L. A. Antidepressant adherence: Are patients taking their medications? Innov Clin Neurosci 9, 41-46 (2012).
6. Frazer, A. & Benmansour, S. Delayed pharmacological effects of antidepressants. Mol Psychiatry 7, S23-28, doi: 10.1038/sj.mp.4001015 (2002). Suppl 1.
7. Braun, C., Bschor, T., Franklin, J. & Baethge, C. Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder. Psychother Psychosom 85, 171-179, doi: 10.1159/000442293 (2016).
8. Seemüller, F. et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 12, 181-189, doi: 10.1017/S1461145708009139 (2009).
9. Rush, A. J. et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: A STAR∗D report. Am J Psychiatry 163, 1905-1917, doi: 10.1176/ajp.2006.163.11.1905 (2006).
10. Price, R. B. et al. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 31, 335-343, doi: 10.1002/da.22253 (2014).
11. DiazGranados, N. et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71, 1605-1611, doi: 10.4088/JCP.09m05327blu (2010).
12. Alberich, S. et al. Efficacy and safety of ketamine in bipolar depression: A systematic review. Rev Psiquiatr Salud Ment (2016).
13. Larkin, G. L. & Beautrais, A. L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14, 1127-1131, doi: 10.1017/S1461145711000629 (2011).
14. Miyaoka, T. et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37, 222-226, doi: 10.1016/j.pnpbp.2012.02.002 (2012).
15. Rosenblat, J. D. et al. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-Analysis. Bipolar Disord 18, 89-101, doi: 10.1111/bdi.2016.18.issue-2 (2016).
16. FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm (Accessed 2016).
17. The Adverse Event Reporting System (AERS): Older Quarterly Data Files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm083765.htm (Accessed 2016).
18. Questions and Answers on FDA's Adverse Event Reporting System (FAERS) http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm (Acessed 2016).